Seasoned healthcare-focused investor and operator with experience executing growth equity and venture investments across biotech, medical devices, and services. Ryan M Palmer brings operational leadership in scaling commercial strategies, board governance, and capital formation for early-to-late-stage companies. Known for sourcing cross-border partnerships, structuring growth rounds and driving exit readiness through commercialization milestones and strategic M&A. Relevant to funds targeting healthcare innovation, commercialization risk reduction and value creation pre-exit.
Seasoned healthcare-focused investor and operator with experience executing growth equity and venture investments across biotech, medical devices, and services. Ryan M Palmer brings operational leadership in scaling commercial strategies, board governance, and capital formation for early-to-late-stage companies. Known for sourcing cross-border partnerships, structuring growth rounds and driving exit readiness through commercialization milestones and strategic M&A. Relevant to funds targeting healthcare innovation, commercialization risk reduction and value creation pre-exit.
Preference for healthcare growth equity and venture investments that prioritize commercialization pathways and measurable clinical or market milestones. Capital is allocated to companies where operational intervention—commercial scaling, KOL engagement, regulatory‑de-risking and cross‑border partnerships—can materially accelerate value. Investment style favors staged financings, lead or active board roles, syndication to optimize capital and exit optionality, and sector focus on biotech, medical devices and services with a 3–7 year exit horizon driven by M&A or strategic partnerships.
Preference for healthcare growth equity and venture investments that prioritize commercialization pathways and measurable clinical or market milestones. Capital is allocated to companies where operational intervention—commercial scaling, KOL engagement, regulatory‑de-risking and cross‑border partnerships—can materially accelerate value. Investment style favors staged financings, lead or active board roles, syndication to optimize capital and exit optionality, and sector focus on biotech, medical devices and services with a 3–7 year exit horizon driven by M&A or strategic partnerships.
| Trades 1074 | Longs Won 785/1074 73% | Profit Factor 8.12 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $379,224.82 |
| Average Win $109,017.75 | Best Trade (Oct 14) $7.81M | Sharpe Ratio -60.38 |
| Average Loss -$36,488.95 | Worst Trade (Dec 30) -$419,607.49 | Z-Score 8.93 (100%) |
| Commissions $0 | Avg. Trade Length 1y 2m 3d | Expectancy $69,863.71 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% |
| Consecutive Losing Trades | 6,944 | 6,250 | 5,556 | 4,861 | 4,167 | 3,472 | 2,778 | 2,083 | 1,389 | 694 |
| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
AAMI Acadian Asset Management Inc. | 8,368 | $234,929.72 | $776,215.68 | - | $541,285.96 | 230.4% | +1.822% |
AAPL Apple Inc. | 793 | $215,653 | $271,206 | - | $55,553 | 25.76% | -0.28% |
ABBV AbbVie Inc. | 12,838 | $2.02M | $3.64M | - | $1.62M | 79.93% | -0.051% |
ADTN Adtran Holdings, Inc. | 35,601 | $538,643.13 | $232,474.53 | - | -$306,168.6 | -56.84% | -1.657% |
AMAT Applied Materials, Inc. | 1,199 | $431,154 | $515,581.99 | - | $84,427.99 | 19.58% | -3.721% |
AMGN Amgen Inc. | 717 | $223,381 | $311,192.34 | - | $87,811.34 | 39.31% | +1.856% |
APAM Artisan Partners Asset Management Inc. | 60,922 | $2.36M | $1.99M | - | -$366,194.18 | -15.51% | +3.166% |
APP AppLovin Corporation Class A Common Stock | 845 | $150,629.72 | $236,000.05 | - | $85,370.33 | 56.68% | +6.522% |
AVGO Broadcom Inc. | 8,285 | $924,829.69 | $2.85M | - | $1.93M | 208.4% | -0.575% |
BBY Best Buy Co., Inc. | 39,694 | $2.62M | $3.74M | - | $1.11M | 42.42% | +5.701% |
BDEC Innovator U.S. Equity Buffer ETF | 5,171 | $197,791.22 | $285,568.47 | - | $87,777.25 | 44.38% | +0.324% |
BE Bloom Energy Corporation | 2,211 | $313,279.41 | $522,448.24 | - | $209,168.83 | 66.77% | -1.272% |
BHP BHP Group Ltd. | 38,145 | $1.94M | $3.16M | - | $1.22M | 62.95% | -0.42% |
BKE Buckle Inc. | 8,228 | $385,428.52 | $383,424.8 | - | -$2,003.72 | -0.52% | +5.168% |
BKNG Booking Holdings Inc. | 2,616 | $402,563.46 | $433,811.28 | - | $31,247.82 | 7.76% | +3.205% |
BMAY Innovator U.S. Equity Buffer Fund | 13,001 | $518,992.6 | $636,268.94 | - | $117,276.34 | 22.6% | +0.245% |
BMY Bristol-Myers Squibb Company | 43,542 | $2.22M | $2.64M | - | $413,677.32 | 18.6% | +2.21% |
BRK-B Berkshire Hathaway Inc. | 1,163 | $434,974.18 | $611,656.59 | - | $176,682.41 | 40.62% | -0.08% |
BTI British American Tobacco p.l.c. ADR | 40,936 | $1.25M | $2.37M | - | $1.12M | 89.68% | +2.391% |
BW Babcock & Wilcox Enterprises, Inc. | 23,309 | $328,657 | $115,845.73 | - | -$212,811.27 | -64.75% | +2.474% |